This article was originally published in The Gray Sheet
Executive SummaryNovartis subsidiary Ciba Vision acquires an initial 10% equity stake in the ophthalmic product start-up. The move gives Ciba exclusive marketing and distribution rights to Medennium's PRL (phakic refractive lens), an intraocular lens designed for implantation into the posterior chamber of the eye to correct hyperopia and myopia. Phase II trials for the PRL are ongoing in the U.S., with Phase III studies slated to begin in early 2001, Ciba says. A CE mark is expected sometime in 2001
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.